Stock.io

Open

High

Low

Volume

Average Volume

P/E

Forward P/E

Market cap

52W H

52W L

Beta

Dividend yield

Website

Sector

Industry

Number of employees

Short term outlook

Long term outlook

News:

Loading details...

Open48.88

High50.08

Low45.77

Volume4.35M

Average Volume2.02M

P/E-

Forward P/E-15.61

Market cap2.92B

52W H71.50

52W L8.73

Beta1.00

Dividend yield-

Open

High

Low

Volume

Average Volume

P/E

Forward P/E

Market cap

52W H

52W L

Beta

Dividend yield

uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Websitehttps://www.uniqure.com

SectorHealthcare

IndustryBiotechnology

Number of employees

221

Short term outlookBullish

Long term outlookBullish

Website

Sector

Industry

Number of employees

Short term outlook

Long term outlook

News:

QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
Zacks
•
1 day and 1 hour ago
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
GlobeNewswire
•
1 day and 8 hours ago
uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk
Simply Wall St.
•
1 day and 9 hours ago
uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update
Simply Wall St.
•
1 day and 13 hours ago
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
Zacks
•
2 days and 8 hours ago